326 related articles for article (PubMed ID: 30362919)
1. Evaluating the Presence of Cognitive Biases in Health Care Decision Making: A Survey of U.S. Formulary Decision Makers.
Mezzio DJ; Nguyen VB; Kiselica A; O'Day K
J Manag Care Spec Pharm; 2018 Nov; 24(11):1173-1183. PubMed ID: 30362919
[TBL] [Abstract][Full Text] [Related]
2. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
3. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
6. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
[TBL] [Abstract][Full Text] [Related]
7. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
8. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
Garrison LP; Neumann PJ; Willke RJ
J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
[TBL] [Abstract][Full Text] [Related]
9. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
10. Decision-making in Orthopaedic Oncology: Does Cognitive Bias Affect a Virtual Patient's Choice Between Limb Salvage and Amputation?
Gurich RW; Cizik AM; Punt SE; Namekata M; Johnson CN; Symons RG; Brewer EG; Thompson MJ
Clin Orthop Relat Res; 2020 Mar; 478(3):506-514. PubMed ID: 31173578
[TBL] [Abstract][Full Text] [Related]
11. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
Watkins JB; Minshall ME; Sullivan SD
J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
Choi Y; Navarro RP
J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
[TBL] [Abstract][Full Text] [Related]
13. Payer perceptions on the use of economic models in oncology decision making.
Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
[No Abstract] [Full Text] [Related]
14. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
[TBL] [Abstract][Full Text] [Related]
15. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
[No Abstract] [Full Text] [Related]
16. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
17. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
18. Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational Therapies.
Brixner D; Woodward TC; Seifter N; Biskupiak J; Marciniak M; Neumann P; Oderda G
J Manag Care Spec Pharm; 2019 Feb; 25(2):164-173. PubMed ID: 30698089
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics and formulary decision making.
Sanchez LA
Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
[TBL] [Abstract][Full Text] [Related]
20. Use of health-related quality of life information in managed care formulary decision-making.
Wu WK; Sause RB; Zacker C
Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
